Epizyme Announces Leadership Transition for Finance Organization
August 15 2017 - 6:30AM
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical
company creating novel epigenetic therapies, today announced a
leadership transition plan for its finance organization. Andrew E.
Singer, executive vice president, finance and administration and
chief financial officer of Epizyme, will be leaving the Company at
the end of August to pursue other business opportunities. As part
of this transition, Susan Graf, chief business officer of Epizyme,
will assume responsibility for the finance organization going
forward, including Epizyme’s financial reporting and analysis
group.
In addition, the Company plans to appoint a senior vice
president of finance who will report to Ms. Graf beginning in
September, and has also secured the professional finance consulting
services of Danforth Advisors during this transition.
“We are grateful to Andy for his contributions to Epizyme, which
include helping to establish a number of external collaborations,
strengthening the company’s financial position and serving as a key
member of the management team overseeing Epizyme’s growth and
strategy,” said Robert Bazemore, president and chief executive
officer of Epizyme. “I want to thank Andy for his tenure and wish
him well in his future endeavors. As we look ahead, I believe that
our experienced management team possesses the skills and know-how
to execute on the drivers for both short and long-term growth,
including continuing to advance our robust tazemetostat clinical
program, preparing for our first New Drug Application submission
planned for 2018 and transitioning into a fully integrated,
commercial-stage company.”
About Epizyme, Inc. Epizyme, Inc. is a
clinical-stage biopharmaceutical company committed to rewriting
cancer treatment through novel epigenetic medicines. Epizyme is
broadly developing its lead product candidate, tazemetostat, a
first-in-class EZH2 inhibitor, with studies underway in both solid
tumors and hematological malignancies, as a monotherapy and
combination therapy and in relapsed and front-line disease. Using
the Company's proprietary platform, Epizyme has pioneered the
identification and development of small molecule inhibitors of
chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are
part of the system of gene regulation, referred to as epigenetics,
that controls gene expression. Genetic alterations can result in
changes to the activity of CMPs, which can allow cancer cells to
grow and proliferate. By focusing on the genetic drivers of
cancers, Epizyme's science seeks to match targeted medicines with
the specific patients that need it. For more information, visit
www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Epizyme, Inc. and other statements
containing the words "anticipate," "believe," "estimate," "expect,"
"intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: uncertainties inherent in the initiation of
future clinical studies and in the availability and timing of data
from ongoing clinical studies; whether interim results from a
clinical trial will be predictive of the final results of the
trial; whether results from preclinical studies or earlier clinical
studies will be predictive of the results of future trials; whether
results from clinical studies will warrant meetings with regulatory
authorities or submissions for regulatory approval; expectations
for regulatory approvals to conduct trials or to market products;
whether the Company's cash resources will be sufficient to fund the
Company's foreseeable and unforeseeable operating expenses and
capital expenditure requirements; other matters that could affect
the availability or commercial potential of the Company's
therapeutic candidates; and other factors discussed in the "Risk
Factors" section of the Company's most recent Form 10-Q filed with
the SEC and in the Company's other filings from time to time with
the SEC. In addition, the forward-looking statements included in
this press release represent the Company's views as of the date
hereof and should not be relied upon as representing the Company's
views as of any date subsequent to the date hereof. The Company
anticipates that subsequent events and developments will cause the
Company's views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so.
Contacts:
Cheya Pope, Epizyme, Inc.
media@epizyme.com
617-229-7561
Monique Allaire, THRUST IR
monique@thrustir.com
(617) 895-9511
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2024 to May 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From May 2023 to May 2024